News | News By Subject | News by Disease News By Date | Search News

Cystic fibrosis News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
After Hep C Flop, Has Vertex (VRTX) Learned From Its Past Mistakes?     10/18/2016
Pharma Bro Warned You: Mast Therapeutics (MSTX) Craters After Drug Flunks Phase III Test, Job Cuts Expected     9/22/2016
Vertex (VRTX) Dumps Phase III Cystic Fibrosis Study     8/17/2016
Vertex (VRTX) and Moderna Hammer Out $315 Million+ Deal to Treat Cystic Fibrosis Using mRNA Technology     7/6/2016
FDA Spurns Vertex (VRTX) Application for Expanded Use of Kalydeco     2/5/2016
How Vertex (VRTX)'s Long-Term $500K Gamble Paid Off with a $30 Billion Return     11/18/2015
Vertex (VRTX)'s Success Spurs Startups Corbus and Pulmatrix to Enter Cystic Fibrosis Market     8/18/2015
Watch Out Gilead (GILD), Investors Feel Vertex (VRTX) May Be Biogen (BIIB)'s Good Fit     8/4/2015
Vertex (VRTX) Gets FDA Approval for $259K Per Year CF Drug     7/7/2015
Vertex (VRTX) Poised to Become Profitable Following Expected FDA Approval of Orkambi     7/1/2015
Tiny Parion Sciences Wrangles Lung Pact Worth $1.2 Billion From Vertex (VRTX)     6/8/2015
Corbus Will Interview Twice as Many Candidates in 2015 as Its Ranks Grow     5/29/2015
Your Analyst-Vetted Guide to the Five Blockbuster Drugs the FDA May Approve This Summer     5/28/2015
Vertex (VRTX) Soars After Hours as FDA Panel Backs Cystic Fibrosis Drug Orkambi     5/15/2015
Investors Hold Their Breath as Vertex (VRTX) Defends Newly Branded Cystic Fibrosis Treatment to the FDA     5/12/2015

News from Around the Web
New Life Form Discovered In Saliva Is Linked To Human Disease, University of Washington Study     6/27/2016
VisiVest, A New Connected High-Frequency Chest-Wall Oscillation System, Hill-Rom Reveals     6/22/2016
The Importance Of Implementing CF Newborn Screening Reinforced, McGill University Study     5/5/2016
Researchers Build Promising CF Diagnostic System Using Microsoft's Xbox Kinect Sensors     3/30/2016
Fast, Accurate Cystic Fibrosis Test Developed At Stanford University     2/2/2016
Why Investors Shouldn't Freak Out Over Vertex (VRTX)'s Latest Trial Results     3/24/2015
Garlic Could Help Cure Lung Infection, University of Edinburgh Study     2/25/2015
University of Pittsburgh-Led Study Suggests Cystic Fibrosis Is Two Diseases, One Doesn’t Affect Lungs     7/23/2014
Cystic Fibrosis And Diabetes Link Explained, Lund University Study     6/3/2014
New Drug Target Found for Cystic Fibrosis Lung Disease, BC Children's Hospital Study     11/8/2012
Sea Sponge Chemical Fixes Cystic Fibrosis Defect, McGill University Study     10/29/2012
Differences Seen in Lung Microbes of Cystic Fibrosis Patients, Stanford University Study     10/1/2012
Big Advance Against Cystic Fibrosis: Stem Cell Researchers Create Lung Surface Tissue in a Dish, Massachusetts General Hospital Study     4/6/2012
Student, 16, Invents New Drug Cocktail to Fight Cystic Fibrosis, Wins Canadian Biotech Challenge, National Research Council of Canada laboratories Reveals     5/12/2011
Cystic Fibrosis Patients May Benefit From Combination Therapy Which Provides Hope For Cure Of Dangerous Infections, McMaster University Study     4/25/2011

Press Releases
Vertex (VRTX) Presents Long-Term Data Demonstrating That ORKAMBI (Lumacaftor/Ivacaftor) And KALYDECO (Ivacaftor) Show The Potential To Modify The Progression Of CF     10/27/2016
ProQR Therapeutics B.V. (PRQR) Announces That QR-010 Meets The Primary Endpoint In A Proof Of Concept Study Of Homozygous F508del Cystic Fibrosis Patients     10/27/2016
Catabasis (CATB) Presents Positive Data For CAT-5571, A Novel Activator Of Autophagy, As A Potential Oral Treatment For Cystic Fibrosis At The 30th Annual North American Cystic Fibrosis Conference     10/27/2016
Synedgen Reports Promising Data Demonstrating Biofilm Disruption And Potentiation Of Antibacterial Activity In Burkholderia Clinical Isolates Treated With Glycopolymer-Based Therapeutics     10/27/2016
Synedgen Announces Presentation Of Data At NACFC Demonstrating Prevention Of Gastrointestinal Complications With Glycopolymer-Based Therapeutics In A Preclinical Model Of Cystic Fibrosis     10/27/2016
Vertex (VRTX) to Test Next-Generation CF Drugs by End of Year     10/26/2016
Vertex (VRTX) Announces Planned Initiation Of Phase 2 Studies Evaluating The Next-Generation Correctors VX-440 And VX-152 In Triple Combination Regimens To Treat The Underlying Cause Of Cystic Fibrosis     10/26/2016
Good Start Genetics Announces New Tier Of Offerings Making Genetic Testing More Accessible For Couples Planning A Family     10/13/2016
Vertex (VRTX) Release: FDA Approves ORKAMBI (Lumacaftor/Ivacaftor) For Use In Children With Cystic Fibrosis Ages 6 Through 11 Who Have Two Copies Of The F508del Mutation     9/29/2016
Concert Pharmaceuticals, Inc. (CNCE) Announces Upcoming Poster Presentation At North American Cystic Fibrosis Conference     9/23/2016
Exemplar Genetics ExeGen Cystic Fibrosis Research Model Utilized In Development Of New Gene Therapy Treatments     9/13/2016
Raptor (RPTP) Presents Results From Meta-Analysis Demonstrating Efficacy Of QUINSAIR Comparable To Other Approved, Inhaled Antibiotics In Cystic Fibrosis Patients     9/7/2016
Pulmatrix Receives Orphan Drug Designation From The FDA For Inhaled Drug To Treat Pulmonary Fungal Infections In Cystic Fibrosis Patients     8/18/2016
Children's Hospital Los Angeles Release: DNA Sequencing Uncovers Latent Risk For Developing Cystic Fibrosis     7/26/2016
PTC Therapeutics (PTCT) Provides Regulatory Update On Translarna (Ataluren)     7/25/2016